Shots:
- The US FDA has approved IND application of ABT-301 to initiate P-I/II trial for pts with metastatic colorectal cancer (mCRC)
- Trial will assess ABT-301 + Tevimbra (provided by Beone) + Avastin in ~66 pts across Taiwan & Australia, with proficient mismatch repair (pMMR) or non-microsatellite instability-high (non-MSI-H) mCRC
- Additionally, Anbogen is pursuing global licensing, strategic partnerships, & Series B fundraising to accelerate commercialization & global expansion of ABT-301
Ref: PRNewsWire | Image: Anbogen Therapeutics| Press Release
Related News:- Novo Nordisk’s Alhemo Receives the US FDA’s Approval for Hemophilia A or B (HA/HB) Without Inhibitors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
